Literature DB >> 33442842

GABAB Receptors and Drug Addiction: Psychostimulants and Other Drugs of Abuse.

Xiaofan Li1, Paul A Slesinger2.   

Abstract

Metabotropic GABAB receptors (GABABRs) mediate slow inhibition and modulate synaptic plasticity throughout the brain. Dysfunction of GABABRs has been associated with psychiatric illnesses and addiction. Drugs of abuse alter GABAB receptor (GABABR) signaling in multiple brain regions, which partly contributes to the development of drug addiction. Recently, GABABR ligands and positive allosteric modulators (PAMs) have been shown to attenuate the initial rewarding effect of addictive substances, inhibit seeking and taking of these drugs, and in some cases, ameliorate drug withdrawal symptoms. The majority of the anti-addiction effects seen with GABABR modulation can be localized to ventral tegmental area (VTA) dopamine neurons, which receive complex inhibitory and excitatory inputs that are modified by drugs of abuse. Preclinical research suggests that GABABR PAMs are emerging as promising candidates for the treatment of drug addiction. Clinical studies on drug dependence have shown positive results with GABABR ligands but more are needed, and compounds with better pharmacokinetics and fewer side effects are critically needed.
© 2020. Springer Nature Switzerland AG.

Entities:  

Keywords:  Dopamine; Positive allosteric modulators (PAMs); Synaptic plasticity; Ventral tegmental area (VTA)

Mesh:

Substances:

Year:  2022        PMID: 33442842     DOI: 10.1007/7854_2020_187

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  229 in total

Review 1.  [GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators].

Authors:  Roberta Agabio; Giancarlo Colombo
Journal:  Psychiatr Pol       Date:  2015 Mar-Apr       Impact factor: 1.657

2.  Acute cocaine exposure weakens GABA(B) receptor-dependent G-protein-gated inwardly rectifying K+ signaling in dopamine neurons of the ventral tegmental area.

Authors:  Devinder Arora; Matthew Hearing; Desirae M Haluk; Kelsey Mirkovic; Ana Fajardo-Serrano; Martin W Wessendorf; Masahiko Watanabe; Rafael Luján; Kevin Wickman
Journal:  J Neurosci       Date:  2011-08-24       Impact factor: 6.167

3.  Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal.

Authors:  S Akhondzadeh; S A Ahmadi-Abhari; S M Assadi; O L Shabestari; A R Kashani; Z M Farzanehgan
Journal:  J Clin Pharm Ther       Date:  2000-10       Impact factor: 2.512

4.  Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial.

Authors:  S A Ahmadi-Abhari; S Akhondzadeh; S M Assadi; O L Shabestari; Z M Farzanehgan; A Kamlipour
Journal:  J Clin Pharm Ther       Date:  2001-02       Impact factor: 2.512

5.  Reduced G-protein coupling to the GABAB receptor in the nucleus accumbens and the medial prefrontal cortex of the rat after chronic treatment with nicotine.

Authors:  Diana Amantea; Michela Tessari; Norman G Bowery
Journal:  Neurosci Lett       Date:  2004-01-30       Impact factor: 3.046

6.  Contribution of ventral tegmental GABA receptors to cocaine self-administration in rats.

Authors:  E N Backes; S E Hemby
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

7.  GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice.

Authors:  Sawako Arai; Kazuhiro Takuma; Hiroyuki Mizoguchi; Daisuke Ibi; Taku Nagai; Hiroyuki Kamei; Hyoung-Chun Kim; Kiyofumi Yamada
Journal:  Eur J Pharmacol       Date:  2008-11-12       Impact factor: 4.432

8.  Reduced inhibitory action of a GABAB receptor agonist on [3H]-dopamine release from rat ventral tegmental area in vitro after chronic nicotine administration.

Authors:  Diana Amantea; Norman G Bowery
Journal:  BMC Pharmacol       Date:  2004-10-20

9.  Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581].

Authors:  Seyed Mohammad Assadi; Reza Radgoodarzi; Seyed Ali Ahmadi-Abhari
Journal:  BMC Psychiatry       Date:  2003-11-18       Impact factor: 3.630

Review 10.  Dopamine signaling in reward-related behaviors.

Authors:  Ja-Hyun Baik
Journal:  Front Neural Circuits       Date:  2013-10-11       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.